Brokers Set Expectations for HeartSciences Q4 Earnings

HeartSciences Inc. (NASDAQ:HSCS) – Equities researchers at Maxim Group issued their Q4 2026 earnings per share (EPS) estimates for shares of HeartSciences in a research note issued on Wednesday, July 1st. Maxim Group analyst A. Klee anticipates that the company will post earnings per share of ($0.78) for the quarter. The consensus estimate for HeartSciences’ current full-year earnings is ($3.28) per share. Maxim Group also issued estimates for HeartSciences’ Q1 2027 earnings at ($0.81) EPS, Q2 2027 earnings at ($0.73) EPS, Q3 2027 earnings at ($0.74) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($2.93) EPS, Q1 2028 earnings at ($0.72) EPS, Q2 2028 earnings at ($0.67) EPS, Q3 2028 earnings at ($0.51) EPS, Q4 2028 earnings at ($0.35) EPS and FY2028 earnings at ($2.21) EPS.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research report on Wednesday, June 24th. Ascendiant Capital Markets lowered their price target on shares of HeartSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.00.

HeartSciences Stock Down 5.1%

HeartSciences stock opened at $2.79 on Friday. The stock’s 50 day moving average price is $2.05 and its 200 day moving average price is $2.50. HeartSciences has a 1-year low of $1.63 and a 1-year high of $6.47. The company has a market cap of $8.87 million, a PE ratio of -0.56 and a beta of 1.78. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 1.04.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC bought a new position in shares of HeartSciences Inc. (NASDAQ:HSCS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 17.24% of the company’s stock.

Key Headlines Impacting HeartSciences

Here are the key news stories impacting HeartSciences this week:

• Neutral Sentiment: Maxim Group initiated or updated earnings forecasts for HeartSciences, projecting losses of $0.78 per share in Q4 2026, $0.81 in Q1 2027, $0.73 in Q2 2027, $0.74 in Q3 2027, and $0.67 in Q4 2027, followed by FY2027 losses of $2.93 per share. HeartSciences stock page
• Neutral Sentiment: The firm also forecast narrower losses in FY2028, estimating $2.21 per share, with quarterly losses of $0.72 in Q1 2028, $0.67 in Q2 2028, $0.51 in Q3 2028, and $0.35 in Q4 2028, suggesting improving profitability expectations over time. HeartSciences stock page
• Neutral Sentiment: Because these estimates are still negative but trending less so, the reports may support a modestly constructive view on the stock, though the updates do not by themselves signal a major catalyst. HeartSciences stock page

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.